Beijing Mabworks Biotech Co., Ltd.
Privately held: no public share price
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CD20Monoclonal antibody | Systemic Lupus ErythematosusFollicular LymphomaPrimary Membranous Nephropathy | |
| Phase 1/2 | GPRC5D x BCMA x CD3 | Multiple Myeloma |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
2028 (1)
December 2028 (1)
Est. primary completion 2028-12 · NCT07405970 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
4 June 2026Priority reviewObinutuzumab beta (Bejescin)NMPA marketing application for obinutuzumab beta (Bejescin) in primary membranous nephropathy under priority review (reported 2026-06-04)
CN, NMPA · Beijing Mabworks Biotech · Source ↗
Financial reports
No financial reports recorded.